Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV) and confirmed by the Conners' Adult ADHD Diagnostic Interview for DSM IV~* Described chronic course of ADHD symptomatology from childhood to adulthood, with some symptoms present before age 7 years and continue to meet DSM-IV criteria at the time of assessment~* CAARS score of at least or equal to 24 as determined by investigator at screening visit~* Patient agrees to take only the supplied study drug as treatment for ADHD during the study~* Patient agrees not to initiate a new behavioral modification program during the study or if currently using a behavioral modification program agrees not to change this program during the study.~Exclusion Criteria:~* Known to be a non-responder to methylphenidate, or patient has a child known to be a non-responder to methylphenidate~* Has been treated with any methylphenidate-containing medication within 1 month of screening visit~* Participation in and premature withdrawal from 42603ATT3002, CR002479 or 42603ATT3004, CR011068 study~* Known allergy or hypersensitivity to methylphenidate, or components of PR OROS methylphenidate~* Any clinically unstable psychiatric condition including, but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), anti-social personality disorder, borderline personality disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
- 002 (Type: EXPERIMENTAL): prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
- 003 (Type: PLACEBO_COMPARATOR): Placebo 2xplacebo once daily for 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).